Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes

a pathophysiology-based review of clinical implications

Bajaj, Harpreet S.a , b; Al-Jabri, Badrc; Verma, Subodhd , e

doi: 10.1097/HCO.0000000000000562
SPECIAL COMMENTARIES

Purpose of review Cardiovascular outcome trials (CVOT) with glucagon-like peptide-1 receptor agonists (GLP-1 RA) have had variable results to date: with two CVOTs being positive and two concluding neutrality/safety results for primary cardiovascular outcome. Mechanistic insights delving into the pathophysiologic mechanisms that may link certain GLP-1 RA to cardioprotection may help define the application of this medication class in clinical practice based on the evidence of the CVOT data. We discuss the various mechanisms that have been postulated from animal and preclinical human studies to help explain the benefits observed in CVOTs with GLP-1 RA.

Recent findings Cardiovascular benefits of GLP-1 may be dependent on the complex interactions of this incretin hormone with the atherosclerotic pathways, either through its direct actions on the cardiovascular system or indirectly through intermediary actions on metabolism, energy transfer, inflammation or thrombosis. An indirect metabolic action of GLP-1 RA, via an initial step of achieving glucose homeostasis or balancing inter-organ energy metabolism, leading to favorable downstream effects on the inflammation-thrombosis pathways, finally impacting atherosclerosis, appears compelling.

Summary In addition to their metabolic benefits, specific GLP-1 RA medications offer cardiovascular protection in high-risk type 2 diabetes. Further mechanistic studies and clinical trials in lower cardiovascular risk populations may help cement the place of this class of medications across the spectrum of type 2 diabetes.

aLMC Diabetes & Endocrinology, Brampton

bLeadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada

cKing Saud University, Riyadh

dDivision of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital

eDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada

Correspondence to Harpreet S. Bajaj, MD, MPH, FACE, LMC Diabetes & Endocrinology, 2979 Bovaird Dr E., Brampton, ON L6S 0C6, Canada. Tel: +1 905 595 0560; fax: +1 905 595 0562; e-mail: harpreet.bajaj@lmc.ca

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.